Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
1.530
+0.020 (1.32%)
At close: Oct 9, 2025, 4:00 PM EDT
1.530
0.00 (-0.01%)
After-hours: Oct 9, 2025, 4:12 PM EDT
PACB Revenue
Pacific Biosciences of California had revenue of $39.77M in the quarter ending June 30, 2025, with 10.42% growth. This brings the company's revenue in the last twelve months to $156.11M, down -17.35% year-over-year. In the year 2024, Pacific Biosciences of California had annual revenue of $154.01M, down -23.19%.
Revenue (ttm)
$156.11M
Revenue Growth
-17.35%
P/S Ratio
2.79
Revenue / Employee
$271,496
Employees
575
Market Cap
459.57M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 154.01M | -46.51M | -23.19% |
Dec 31, 2023 | 200.52M | 72.22M | 56.29% |
Dec 31, 2022 | 128.30M | -2.21M | -1.69% |
Dec 31, 2021 | 130.51M | 51.62M | 65.43% |
Dec 31, 2020 | 78.89M | -12.00M | -13.20% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PACB News
- 1 day ago - Long Life Family Study Taps PacBio HiFi Sequencing to Unlock Genetic and Epigenetic Clues to Exceptional Longevity - GlobeNewsWire
- 2 days ago - PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs - GlobeNewsWire
- 17 days ago - PacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes - GlobeNewsWire
- 4 weeks ago - Pacific Biosciences Of California, Inc. (PACB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 5 weeks ago - PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow - GlobeNewsWire
- 2 months ago - Pacific Biosciences of California, Inc. (PACB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - PacBio to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models - GlobeNewsWire